Skip to main content

Table 2 Baseline characteristics of clinical trials associated with the changing year (n = 277)

From: The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov

Characteristics Number of trials (%) P value
Before to 2007 year 2008–2017 year
Trial phase 0.048
Phase I/II 10 (10.4) 38 (21.0)  
Phase II 78 (81.3) 122 (67.4)  
Phase II/III 0 (0) 4 (2.2)  
Phase III 8 (8.3) 17 (9.4)  
Sponsor 0.215
NIH 16 (16.7) 17 (9.4)  
Industry 20 (20.8) 40 (22.1)  
Other 60 (62.5) 124 (68.5)  
Number of centers 0.560
1 32 (33.3) 65 (35.9)  
2 1 (1.0) 5 (2.8)  
multicenter 63 (65.6) 111 (61.3)  
Number of arms 0.007
1 79 (82.3) 117 (64.6)  
2 13 (13.5) 54 (29.8)  
≥3 4 (4.2) 10 (5.5)  
Treatment allocation 0.002
Non-randomized 83 (86.5) 126 (69.6)  
Randomized 13 (13.5) 55 (30.4)  
Masking 0.024
Open-label 94 (97.9) 164 (90.6)  
Double-blind 2 (2.1) 17 (9.4)  
Region < 0.001
United states 77 (80.2) 109 (60.2)  
Europe 18 (18.8) 47 (26.0)  
Asia 1 (1.0) 25 (13.8)  
Therapy
Chemotherapy 55 (57.3) 40 (22.1) < 0.001
Target therapy /immunology therapy 36 (37.5) 130 (71.8)  
other 5 (5.2) 11 (6.1)  
  1. Percentage of trial characteristics with each inclusion criteria group. Chi-squared test was used for class variables NIH, National Institutes of Health